#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #DLBCL

ADC Therapeutics Reports Financial Results for Q2 2026

ADC Therapeutics SA, a pioneering enterprise in the specialty of antibody-drug conjugates, announced its financial results for the second quarter of 2026, along with insights into ongoing developments within the organization. The company reported a net product revenue of $18.6 million, a solid improvement
from $18.1 million in the previous year, reflecting steady growth and resilience in its operations.

Financial Overview

As of June 30, 2026, ADC Therapeutics had cash and cash equivalents totaling $219.1 million, underscoring its financial stability with a cash runway anticipated to last well into 2028. The company discussed its strategic focus on enhancing the commercial viability of ZYNLONTA®, which is currently used in the treatment of diffuse large B-cell lymphoma (DLBCL), and its evaluations aimed at advancing this product into earlier treatment lines. The Q2 results indicate a broader alignment with previous quarters' commercial performance, showing strong operational discipline and an emphasis on cost-reduction strategies.

Regulatory Path and Upcoming Milestones

In June 2026, ADC Therapeutics engaged in a pre-supplemental Biologics License Application (sBLA) meeting with the U.S. Food and Drug Administration (FDA), addressing the clinical data generated in the LOTIS-5 trial. This meeting resulted in insights into the regulatory approach moving forward, leaving ADC Therapeutics optimistic on their trajectory towards obtaining full approval for ZYNLONTA as a monotherapy for patients with DLBCL.

ADC disclosed its ongoing assessment of LOTIS-7, where enrollment was completed recently. The trial evaluates the efficacy of ZYNLONTA in combination with glofitamab (COLUMVI®) in patients with relapsed/refractory DLBCL. The company is gearing up for a Phase 3 trial based on promising results from these studies.

Cost Management and Strategic Initiatives

In alignment with the need for ongoing operational efficiency, ADC Therapeutics announced a strategic reorganization, leading to a 17% reduction in workforce aimed at achieving approximately $10 million in annualized cost savings. This reorganization is built upon the anticipated competition and innovation in ADC therapies and underscores the company’s commitment to its clinical, regulatory, and manufacturing objectives despite external pressures.

In addition, the organization is making strides in investigator-initiated trials that focus on various B-cell malignancies, paving the way to broaden ZYNLONTA's therapeutic applications. The results from these studies are expected to be presented by the end of the year.

Looking Ahead

With confidence in its strategic positioning, ADC Therapeutics is aiming for potential compendia inclusion beginning in 2027, further establishing ZYNLONTA's role in the treatment landscape for DLBCL. The financial report articulates a clear signal of continued enhancement in product revenues while keeping a vigilant eye on operational costs and advancing clinical successes.

Conclusion

ADC Therapeutics exhibits a positive momentum in their latest financial results, with critical advancements in regulatory discussions and a commitment to optimizing costs. As they prepare to present significant clinical trial data this year, investors and stakeholders continue to look forward to the company's innovative contributions to oncology care worldwide.

For regular updates, the company invites interested parties to join their upcoming conference call and participate via their investor relations page to stay abreast of ongoing developments.